Annex 6, Annex 15 & Quality Maturity | Edition 30

Introduction

Over the last two weeks, the biggest development in the Help Me GMP community has been the continued rollout of the GMP Conversations podcast series, using short, focused episodes to walk through core EU GMP expectations and how they translate into day-to-day control.

This matters because inspectors rarely challenge sites on whether they can quote guidance. They challenge whether the Pharmaceutical Quality System (PQS) is working, whether decisions are evidence-based, and whether staff behaviour matches procedures when nobody is watching.

This newsletter is designed to slow things down, add context, and reinforce what “good” looks like in practice. YouTube and podcast learning can support understanding and confidence, but they do not replace controlled training, authorised procedures, or documented evidence within a GMP system.

From the Help Me GMP YouTube Channel

• GMP Conversations Podcast Ep 10: Sampling Annex 8 A practical discussion of sampling as a GMP control, focusing on starting materials and the link between sampling design, contamination control, identity assurance, and patient risk. Inspection link: sampling is not a “QC task”, it is a controlled part of the supply chain and batch release story, and weaknesses typically show up as poor rationale, weak traceability, or inconsistent execution.

• GMP Conversations Podcast Ep 9: You Cannot Outsource GMP Responsibilities Centred on EU GMP Chapter 7 principles and the reality that legal and quality accountability stays with the contract giver and MAH as applicable. Inspection link: inspectors will test supplier qualification, technical agreements, oversight, deviation communication, and how you detect drift over time, not just whether a contract exists.

• GMP Conversations Podcast Ep 8: GMP Chapter 4 Documentation Reinforces documentation as a control mechanism for consistency, traceability, and data integrity, not administrative overhead. Inspection link: documentation failures often sit behind wider findings, including weak investigations, incomplete batch records, uncontrolled rework, and poor training evidence.

• GMP Conversations Podcast Ep 7: Quality Control Covers QC fundamentals as part of the wider PQS: sampling, testing, method control, OOS handling, trending, and release support. Inspection link: inspectors typically probe whether QC decisions are scientifically justified, whether results are trended, and whether laboratory data integrity controls are robust and demonstrable.

• GMP Conversations Podcast Ep 6: GMP Chapter 8 Complaints and Recall A direct link to recall readiness and complaint handling controls. Inspection link: sites are expected to demonstrate fast product traceability, clear decision-making, effective escalation, and evidence that complaints trigger meaningful investigation and CAPA when required.

Link to the full podcast series - https://www.youtube.com/playlist?list=PLZgMtRY8IsM5KfMHERehGT3pTyMZL42dO

Taken together, these episodes help bridge the gap between regulatory text and operational reality: what the guidance expects, what “control” looks like, and what evidence an inspector will ask to see.

News in Pharma (Last 14 Days)

(Exactly 5 items. Regulator-hosted links only.)

EMA concept paper: revision of EU GMP Annex 6 (Medicinal Gases) Why it matters: medicinal gases often sit at the edge of “utility mindset” rather than “medicinal product mindset”. A revision signals ongoing regulatory focus on quality systems, certification, supply chain control, and risk management for gases used clinically and in manufacturing. https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guidelines-good-manufacturing-practice-medicinal-products-annex-6-manufacture-medicinal-gases_en.pdf

EMA concept paper: revision of EU GMP Annex 15 (Qualification and Validation) Why it matters: Annex 15 is the backbone for how firms justify that equipment, utilities, facilities, and processes are fit for intended use across the lifecycle. Any revision activity is a signal to keep validation governance tight, risk-based, and evidence-led, especially around change control, continued verification, and clear rationale. https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guidelines-good-manufacturing-practice-medicinal-products-annex-15-qualification-validation_en.pdf

FDA update: Quality Management Maturity (QMM) programme (CDER) Why it matters: QMM is part of a broader trend toward evaluating quality culture and quality management capability, not only compliance to minimum requirements. It reinforces the expectation that firms understand and control process performance, drive continual improvement, and can demonstrate reliability and resilience. https://www.fda.gov/drugs/pharmaceutical-quality-resources/quality-management-maturity-program

MHRA guidance page update: modifying a clinical trial approval (includes GMP documentation expectations) Why it matters: even outside commercial manufacturing, regulators continue to emphasise that GMP documentation and labelling controls remain fundamental for investigational medicinal products and trial changes. It is another reminder that “clinical” does not mean “informal” when product quality and traceability are in scope. https://www.gov.uk/guidance/clinical-trials-for-medicines-modifying-a-clinical-trial-approval

EMA meeting agenda publication (CHMP, February 2026) referencing inspections as part of the regulatory system Why it matters: while an agenda is not guidance, it signals what is active in the regulatory system. The repeated visibility of inspection activity reinforces that GMP oversight remains a live and routine part of maintaining confidence in quality across products and sites. https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-23-26-february-2026_en.pdf

Recalls and Quality Defects

Important constraint this week: within the last 14 days, I can verify only two licensed-medicine recall notices on MHRA that clearly meet your rules and are not repeats from Edition 29. I cannot reach 5–7 without either (1) widening the time window beyond 14 days, or (2) including additional EU competent authority recall pages that you have not permitted in your constraint set.

Class 2 Medicines Recall: Pinewood Healthcare, Melatonin 3 mg tablets, EL(26)A/10 Jurisdiction: UK (MHRA) Defect/action: Medicines recall (Class 2), details per MHRA notice. https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-sterling-pharmaceuticals-ltd-specials-manufacturer-ms-32515-kidnaps-melatonin-1mg-in-1ml-oral-solution-el-26-a-slash-09

Class 3 Medicines Recall: Norgine Limited, MOVICOL Ease Citrus Powder for oral solution 13.7 g, EL(26)A/08 Jurisdiction: UK (MHRA) Defect/action: Medicines recall (Class 3), details per MHRA notice. https://www.gov.uk/drug-device-alerts/class-3-medicines-recall-norgine-limited-movicol-ease-citrus-powder-for-oral-solution-13-dot-7-g-el-26-a-slash-08

System learning point: even when the defect looks narrow (single product, single presentation), the inspection interest is usually wider, including supplier control, packaging and labelling governance, distribution traceability, escalation pathways, and how quickly the PQS converts a signal into controlled action.

Upcoming Conferences and Training

I have not repeated the event used in Edition 29.

• EMA training and events (official listings) Relevant for regulatory professionals, MAHs, QA and regulatory teams who need visibility of current EMA procedural expectations and planned changes. https://www.ema.europa.eu/en/events

• MHRA events and webinars (official listings) Relevant for UK licence holders and NHS services tracking inspection focus areas, guidance updates, and operational expectations. https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency#events

Audit Readiness Tip

Theme: Sampling and starting materials as an inspection trigger (not a QC afterthought).

Inspectors often treat sampling as the first test of whether your system is actually in control, because it links suppliers, warehouses, QC, and production into one traceable chain.

Reflective checks:

• Can you show a clear, written rationale for sampling plans (what, where, how many, why), and can staff explain it consistently?

• Are sampling tools, containers, labels, and hold times defined and controlled, including protection from mix-up and contamination?

• Do sampling records allow full traceability from supplier batch to internal sample ID to test result to batch disposition?

• When sampling deviates from the plan, is it handled as a governed event (documented, justified, assessed for impact), or treated as “common sense”?

If sampling is weak, identity assurance is weak. If identity assurance is weak, batch release becomes a belief rather than evidence.

Fun GMP Fact

In EU GMP, the credibility of a batch decision is only as strong as the traceability chain behind it. Even technically correct test results can become unusable if the sample identity, handling, or records cannot be proven with reliable data integrity controls.

Call to Action

If this edition is useful, share it with colleagues in QA, QC, production, validation, and aseptic services. The podcast and YouTube episodes are there to support understanding of GMP expectations, and the newsletter is there to keep the link between guidance, inspection mindset, and operational evidence clear.

Kyle Winn WinnPharma / Adam Walker @PharmaQP

Sponsored by W2 Cleanroom Consulting

Contact

Get in touch

info@w2cleanrooms.com

© 2026. All rights reserved.

Our Brands

Free GxP Training

Visit the Help Me GxP YouTube channel